The Medical Marijuana field is a rapidly growing niche market with high potential for profitability. Over time, ArchAngel Capital has conducted top-down research on companies within the Medical Marijuana field that are best positioned to turn a significant profit. As public sentiment continues to gravitate in favor of Medical Marijuana nation-wide, an increasing number of potentially lucrative investment opportunities present themselves. At ArchAngel Capital, we have identified the medical Marijuana field as an ideal candidate for our early-stage adoption criteria. Listed below are four companies that we believe have the potential for returns exceeding 500 percent over the course of the investment cycle.
About Prescription Vending Machines, Inc. DBA Medicine Dispensing Systems, A Subsidiary of Medbox, Inc. [MDBX] Medbox was founded on the principle that all great industries thrive when automated and regulated. Our wholly owned subsidiary, Medicine Dispensing Systems has grossed $13 million dollars since it began doing business in 2010 and later allowed for an acquisition and the establishment of a public company presence in Medbox, Inc. [MDBX]. We have been awarded United States & Canadian Patents concerning the software and hardware related to our medicine dispensing systems. Our company’s founder and CEO have appeared in interviews with CNN, ABCNews, Reuters, BBC, Fox Business, Bloomberg TV, CNBC, Associated Press, NPR, and our company has been featured in articles appearing in Newsweek, Bloomberg BusinessWeek, Los Angeles Times, Chicago Tribune, and the Wall Street Journal, as well as over 30 other news agencies around the world concerning our cutting-edge products and services.Updated.
Steep Hill Halent was launched in early 2008 as Steep Hill Medical Collective to provide quality control services to the medical cannabis industry, which — 12 years after its legalization under California law— consisted of hundreds of businesses providing potentially unsafe herbal products to hundreds of thousands of consumers. The company’s primary mission was and is to protect the public health by providing infrastructure and analytical services to legally authorized distributors and producers of cannabis and to regulators tracking their operations. The company was founded by David Lampach, Addison Demoura and Steve DeAngelo. Corporate headquarters are in Oakland California. The company’s customers are medical cannabis providers anticipating regulation and inspection by public health authorities. In June 2008 the company developed the first microbiological method for determining mold and bacteria levels on cannabis destined for human consumption.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.
Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.
At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.
We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements.
The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.
Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.
In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled “Composition for the Treatment of Neurobehavioral Disorders.” The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with partner company, OmniCanna Health Solutions.
GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group’s lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.
GW has assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW maintains in-house control over all aspects of the cannabinoid product development process – botanical research, extraction technology, formulation into drug delivery technologies, clinical trials and regulatory affairs. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.